Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in pediatric human sarcoma cell lines

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1027-1035

  Waheed Roomi, M ^a   Kalinovsky, Tatiana ^a   Niedzwiecki, Aleksandra ^a   Rath, Matthias ^a  

^a Rath Research Institute   (United States)

Author keywords

Matrix metallo proteinase 2; Matrix metalloproteinase 9; Nutrient mixture; Osteosarcoma MNNG HOS and U 2OS; PMA; Rhabdomyosarcoma RD; Tissue inhibitor of metallo proteinase 2; Urokinase plasminogen activator

Indexed keywords

DIMER; FIBRIN; GELATINASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; UROKINASE;

ARTICLE; CHILDHOOD CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; NUTRIENT; OSTEOSARCOMA; PEDIATRIC SARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA; SARCOMA CELL; UPREGULATION; ZYMOGRAPHY;

BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; FOOD; GELATINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; SARCOMA; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84882291130     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2031     Document Type: Article

References (56)

1. National Institute of Health. PubMed Health: Osteosarcoma. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002616/. Accessed March 18, 2013.
2. Kaste SC, Pratt CB, Cain AM, Jones-Wallace DJ and Rao BN: Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer 86: 1602-1608, 1999.
3. American Cancer Society. Osteosarcoma: What are the survival rates for osteosarcoma? http://www.cancer.org/cancer/osteosarcoma/detailedguide/ osteosarcoma-survival-rates. Accessed March 18, 2013.
4. National Cancer Institute. Childhood Soft Tissue Sarcoma Treatment (PDQ). http://www.cancer.gov/cancertopics/pdq/treatment/child-soft-tissue-sarcoma/ HealthProfessional/. Accessed March 18, 2013.
5. Barr FG: Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 19: 483-491, 1997.
6. Patham DM: Pathologic classification of rhabdomyosarcoma and correlations with molecular studies. Med Pathol 14: 506-514, 2001.
7. Mandell L, Ghavinni F, LaQuaglia M and Exelby P: Prognostic significance of regional lymph node involvements in childhood extremity rhabdomyosarcoma. Med Pediatr Oncol 18: 466-471, 1990.
8. Koscielniak E, Rodary C, Flamant F, Carli M, Treuner J, Pinkerton CR and Grono P: Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med Pediatr Oncol 20: 209-214, 1992.
9. Fidler IJ: Molecular biology of cancer: invasion and metastasis. In: Cancer Principles and Practice of Oncology. De Vita VT, Hellman S and Rosenberg SA (eds). 5th edition. Lippincott-Raven, Philadelphia, PA, pp135-152, 1997.
10. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
11. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (Suppl 16): 15-18, 2002.
12. Chambers AF and Matrisian LM: Changing views on the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997.
13. Kleiner DL and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43 (Suppl): 42s-51s, 1999.
14. Yurchenko PD and Schitny JC: Molecular architecture of basement membranes. FASEB J 4: 1577-1590, 1990.
15. Barsky SH, Siegel GP, Jannotta F, and Liotta LA: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Investig 49: 140-147, 1983.
16. Liotta LA, Tryggvason K, Garbisa A, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
17. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
18. Choong PF, Fernö M, Åkermans M, Willién H, Lngström E, Gustafson P, Alvegrd T and Rydholm A: Urokinase-plasminogen- activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer 69: 268-272, 1996.
19. Benassi MS, Magagnoli G, Ponticelli F, Pazzaglia L, Zanella L, Gamberti G, Ragazzini P, Ferrari C, Mercuri M and Picci P: Tissue and serum loss of metalloproteinases inhibitors in highgrade soft tissue sarcomas. Histol Histopathol 18: 1035-1040, 2003.
20. Taubert H, Würl P, Greither T, Kappler M, Bache M, Lautenschläger C, Füssel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V and Kotzsch M: Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer 102: 731-737, 2010.
21. Stetler-Stevenson WG: The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am 10: 383-392, 2001.
22. Stetler-Stevenson WG: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9: 289-303, 1990.
23. Himelstein BP, Asada N, Carlton MR and Collins MH: Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol 31: 471-474, 1998.
24. Ferrari C, Benassi S, Ponticelli F, Gamberi G, Ragazzini P, Pazzaglia L, Balladelli A, Bertoni F and Picci P: Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years. Acta Orthop Scand 75: 487-491, 2004.
25. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985.
26. Duffy MJ, Duggan C, Mulcahy HE, McDermott EW and O'Higgins NJ: Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 44: 1177-1183, 1998.
27. Rath M and Pauling L: Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs. Orthomolecular Med 7: 17-23, 1992.
28. Andreasen PA, Kjøller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
29. Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Micronutrient synergy-a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev 29: 529-543, 2010.
30. Choong PFM and Nadesapillai AP: Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 415: S46-S58, 2003.
31. Bjornland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O and Maelandsmo GM: Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res 127: 151-156, 2005.
32. Roebuck MM, Helliwell TR, Chaudhry IH, Kalogrianitis S, Carter S, Kemp G, Ritchie DA, Jane MJ and Frostick SP: Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities. Am J Clin Path 123: 405-414, 2005.
33. Diomedi-Carnassei F, Boldrini R, Rava L, Donfrancesco A, Boglino C, Messina E, Dominici C and Callea F: Different patterns of matrix metalloproteinase expression in alveolar versus embryonal rhabdomyosarcoma. J Pediatr Surg 39: 1673-1679, 2004.
34. Roomi MW, Monterrey JC, Kalinovsky T, Niedzwiecki A and Rath M: Inhibition of invasion and MMPs by a nutrient mixture in human cancer cell lines: a correlation study. Exp Oncol 32: 243-248, 2010.
35. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: Effect of ascorbic acid, lysine, proline and green tea extract on human osteosarcoma cell line MNNG-HOS xenografts in nude mice. Med Oncol 23: 411-417, 2006.
36. Amin ARMR, Kucek O, Khuri FR and Shin DM: Perspectives for cancer prevention with natural compounds. J Clin Oncol 27: 2712-2725, 2009.
37. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep 24: 747-757, 2010.
38. Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P and Liu JN: The blockage of high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochem Biophys Acta 1596: 182-192, 2002.
39. Kemberling JK, Hampton JA, Keck RW, Gomez MA and Selman SH: Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. J Urol 170: 773-776, 2003.
40. Sato D and Matsushima M: Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves. Int J Urol 10: 160-166, 2003.
41. Valcic S, Timmermann BN, Alberts DS, Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs 7: 461-468, 1996.
42. Mukhtar H and Ahmed N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 71: 1698s-1702s, 2000.
43. Yang GY, Liao J, Kim K, Yurtow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616, 1998.
44. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Shimikawa R: Effect of (-) epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65: 51-54, 1992.
45. Hara Y: Green Tea: Health Benefits and Applications, Marcel Dekker, New York, Basel, 2001.
46. Kawakami S, Kageyama Y, Fujii Y, Kihara K and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion and MMP 9 production of T24 human bladder cancer cells. Anticancer Res 21: 213-219, 2001.
47. Morini M, Cai T, Aluigi MG, Noonan DM, Masiello L, De Floro S, D'Agostinin F, Albini A and Fassima G: The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers 14: 268-271, 1999.
48. Yoon SO, Kim MM and Chung AS: Inhibitory effects of selenite on invasion of HT 1080 tumor cells. J Biol Chem 276: 20085-20092, 2001.
49. Naidu KA, Karl RC and Coppola D: Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulinlike growth factor 1 receptor. Dig Dis Sci 48: 230-237, 2003.
50. Anthony HM and Schorah CJ: Severe hypovitaminosis C in lung cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer 46: 354-367, 1982.
51. Maramag C, Menon M, Balaji KC, Reddy PG and Laxmanan S: Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis. Prostate 32: 188-195, 1997.
52. Koh WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH: Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res 8: 2487-2493, 1998.
53. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter, E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102: 13604-13609, 2005.
54. Nunez C, Ortiz de Apodaca Y and Ruiz A: Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of consumption of food with an elevated content of this vitamin. Nutr Hosp 10: 68-372, 1995.
55. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183-189, 1996.
56. Cooke JP and Dzau VJ: Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48: 489-509, 1997.